Annals of Oncology 13:1099-1107, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model
1 Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, Oslo; 2 Norwegian Medicines Agency, Oslo, Norway
Received 28 September 2001; revised 10 January 2002; accepted 11 February 2002
Background:
To determine the incidence and risk factors for central nervous system (CNS) relapse in patients with non-Hodgkin’s lymphoma (NHL).
Patients and methods:
Patient records were registered prospectively in successive patients with NHL admitted to the Norwegian Radium Hospital from 1980 to 1996. A total of 2514 patients had no CNS involvement at diagnosis and were treated according to standard protocols. The incidence and risk factors for CNS progression or relapse were examined retrospectively.
Results:
In low-grade (L)-NHL, the risk of CNS involvement was low (2.8%). In high-grade (H)-NHL, lymphoblastic and Burkitt’s NHL patients had a high risk of CNS recurrence (24.4%) at 5 years, and prophylaxis seemed to reduce this risk. For the other patients with H-NHL, the proportion with CNS involvement at 5 years was 5.2%. Multivariate analysis identified five independent risk factors, each present in >5% of patients: elevated serum lactate dehydrogenase, serum albumin <35 g/l, <60 years of age, retroperitoneal lymph node involvement and involvement of more than one extranodal site. If four or five of these risk factors were present, the risk of CNS recurrence was in excess of 25% at 5 years.
Conclusions:
The risk of CNS involvement in this study is comparable with the results from other large series. CNS prophylaxis is not recommended in any subgroup of L-NHL. The risk of CNS involvement among patients with either Burkitt’s or lymphoblastic lymphomas is considerable and these patients should therefore receive intensive chemotherapy including systemic and intrathecal methotrexate. Patients with other types of H-NHL should receive adequate CNS prophylaxis if at least four of the five risk factors identified are present.
Key words: central nervous system involvement, central nervous system prophylaxis, non-Hodgkin’s lymphoma, risk factors
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Yamaguchi, N. Nakamura, R. Suzuki, Y. Kagami, M. Okamoto, R. Ichinohasama, T. Yoshino, J. Suzumiya, T. Murase, I. Miura, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients Haematologica, August 1, 2008; 93(8): 1195 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Bierman, M. L. Villanueva, and J. O. Armitage Diffuse large B-cell lymphoma of the breast: a distinct entity? Ann. Onc., February 1, 2008; 19(2): 201 - 202. [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report Blood, February 1, 2008; 111(3): 1085 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ferrer, F. Bosch, N. Villamor, M. Rozman, F. Graus, G. Gutierrez, S. Mercadal, E. Campo, C. Rozman, A. Lopez-Guillermo, et al. Central nervous system involvement in mantle cell lymphoma Ann. Onc., January 1, 2008; 19(1): 135 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Bjorkholm, H Hagberg, H Holte, S Kvaloy, L Teerenhovi, H Anderson, E Cavallin-Stahl, J Myhre, H Pertovaara, A Ost, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up Ann. Onc., June 1, 2007; 18(6): 1085 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H-T Arkenau, G Chong, D Cunningham, D Watkins, R Agarwal, B Sirohi, M Trumper, A Norman, A Wotherspoon, and A Horwich The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma Ann. Onc., March 1, 2007; 18(3): 541 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Boehme, S Zeynalova, M Kloess, M Loeffler, U Kaiser, M Pfreundschuh, and N Schmitz Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Ann. Onc., January 1, 2007; 18(1): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Spectre, A. Gural, G. Amir, A. Lossos, T. Siegal, and O. Paltiel Central nervous system involvement in indolent lymphomas Ann. Onc., March 1, 2005; 16(3): 450 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Feugier, J. M. Virion, H. Tilly, C. Haioun, G. Marit, M. Macro, D. Bordessoule, C. Recher, M. Blanc, T. Molina, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab Ann. Onc., January 1, 2004; 15(1): 129 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lister, L. E. Abrey, and J. T. Sandlund Central Nervous System Lymphoma Hematology, January 1, 2002; 2002(1): 283 - 296. [Abstract] [Full Text]
|
|